Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience

AIM: To explore and compare the efficacy of standard (300 mg every 2 weeks) and extended (300 mg every 4 weeks) dosing regimens of lanadelumab for long-term prophylaxis of hereditary angioedema (HAE). METHODS: We conducted a retrospective chart review of all patients with HAE on lanadelumab, which i...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuzakouk, Mohamed, Ghorab, Omar, Al-Hameli, Hamad, Salvo, Fulvio, Grandon, Deepa, Maurer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287634/
https://www.ncbi.nlm.nih.gov/pubmed/35891672
http://dx.doi.org/10.1016/j.waojou.2022.100664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287634/
https://www.ncbi.nlm.nih.gov/pubmed/35891672
http://dx.doi.org/10.1016/j.waojou.2022.100664

Ejemplares similares